ロード中...
Objective and subjective measures of dalfampridine efficacy in clinical practice
BACKGROUND: Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patie...
保存先:
| 出版年: | Mult Scler J Exp Transl Clin |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6077903/ https://ncbi.nlm.nih.gov/pubmed/30090641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217318786742 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|